by Brenda Baletti, Ph.D., Childrens Health Defense:
The first post-authorization safety analysis of Pfizer’s Abrysvo RSV vaccine found the average time between vaccination and preterm birth was three days. Two-thirds of reported cases occurred within a week.
A new preprint study shows a statistically significant safety signal for preterm birth associated with Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo.
The first post-authorization safety analysis of Pfizer’s RSV vaccine — RSV prefusion F protein (RSVPreF) — found the average time between vaccination and preterm birth was three days.
Two-thirds of reported cases occurred within a week.